Trillium Therapeutics Inc.
TRIL
TRIL was delisted on the 16th of November, 2021.
26 hedge funds and large institutions have $23.2M invested in Trillium Therapeutics Inc. in 2017 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and 5 closing their positions.
100% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 5
100% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 4
61% more capital invested
Capital invested by funds: $14.4M → $23.2M (+$8.82M)
18% more funds holding
Funds holding: 22 → 26 (+4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$5.81M |
| 2 |
AIC
AWM Investment Company
New York
|
+$5.55M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$3.32M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$3.01M |
| 5 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
+$2.77M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$2.07M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
-$1.4M |
| 3 |
IBT
International Biotechnology Trust
London,
United Kingdom
|
-$336K |
| 4 |
ARTA
A.R.T. Advisors
New York
|
-$143K |
| 5 |
Millennium Management
New York
|
-$62K |
TRIL Hedge Fund Activity: Q2 2017 in Review
26 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Trillium Therapeutics Inc. (TRIL) for Q2 2017, worth a combined $23.2M — up 61% from $14.4M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new TRIL positions and 5 closed out — a net gain of 5 holders — while 8 added to existing stakes and 4 trimmed.
The largest buyer was NEA Management Company, opening a new position worth an estimated $5.81M. The largest seller was Franklin Resources, cutting an estimated $2.07M.
- 26 institutional investors held Trillium Therapeutics Inc. (TRIL) as of Q2 2017, up from 22 in Q1 2017.
- Funds reported $23.2M of Trillium Therapeutics Inc. stock for Q2 2017, up 61% quarter-over-quarter.
- 10 funds opened new Trillium Therapeutics Inc. positions in Q2 2017 and 5 closed out, a net change of +5 holders.
- The largest Trillium Therapeutics Inc. buyer in Q2 2017 was NEA Management Company, an estimated $5.81M added.
- The largest Trillium Therapeutics Inc. seller in Q2 2017 was Franklin Resources, an estimated $2.07M sold.
Based on aggregated 13F filings for Q2 2017.